Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique.
Hellmann
K
K
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control*; D006801:Humans; D017410:Practice Guidelines as Topic; D011837:Radiation-Protective Agents / Q000008:administration & dosage; D011878:Radiotherapy / Q000009:adverse effects; D011929:Razoxane / Q000008:administration & dosage* / Q000009:adverse effects; D015203:Reproducibility of Results; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011837:Radiation-Protective Agents; D011929:Razoxane